Ninth Annual University of Toronto Patent Colloquium

Friday, November 20, 2020 - 10:00 to 15:15

Opening Remarks

10:00 – 10:10 am

Prof. Simon Stern

Director, Centre for Innovation Law & Policy

Faculty of Law, University of Toronto

Chief Justice Paul Crampton

Federal Court of Canada

Panel 1: The Role of the Expert Witness and the Interplay between Counsel and Expert in Preparing Reports: How Much Involvement Is Too Much?

10:10 – 11:40 am

Moderator: Justice Michael Phelan, Federal Court of Canada


David Reive, Miller Thomson LLP

Christopher C. Van Barr, Gowling WLG

Beverley Moore, BLG

Panel 2: Summary Judgement and Summary Trial in Patent Cases

12:00 – 1:30 pm

Moderator: Justice Michael Manson, Federal Court of Canada


Adam Bobker, Bereskin & Parr LLP

Yael Bienenstock, Torys LLP

Mark Davis, Norton Rose Fulbright LLP

Panel 3: Patent Litigation by Zoom, Pros and Cons

1:45 – 3:15 pm

Moderator: Justice Catherine Kane, Federal Court of Canada


Sana Halwani, Lenczner Slaght

Steve Mason, McCarthy Tetrault

Alan Macek, DLA Piper

Closing Remarks

3:15 pm

Prof. Simon Stern

Director, Centre for Innovation Law & Policy

Faculty of Law, University of Toronto


Eighth Annual University of Toronto Patent Colloquium

Friday, November 15, 2019 - 8:30am to 4:00pm

Location: Rosalie Silberman Abella Moot Court Room, Jackman Law Building, 78 Queen's Park


  • The Ins and Outs of Non-Infringing Alternatives
  • Protective Agreements and Confidentiality Orders – The State of Play
  • File Wrapper History (coming to a theatre near you: what it will mean)



Sixth Annual Patent Colloquium

Friday, November 9, 2018


Sixth Annual Patent Colloquium

Friday, November 3, 2017 - 08:30 to 17:00

Location: Moot Court Room, Jackman Law Building

Sixth Annual Patent Colloquium

Friday, November 3, 2017

  1. Farewell Notice of Compliance (NOC) applications. Hello NOC trials.

The Patented Medicines (Notice of Compliance) Regulations were introduced in 1993 to protect the rights of brand name pharmaceutical patent holders and to facilitate the entry of generic drugs onto the market. But these Regulations have long been criticized as being unfair to patent holders. Implementation of the Comprehensive Economic and Trade Agreement (CETA) brought changes to the PM(NOC) Regulations and the Patent Act, including the replacement of judicial review applications with full trial proceedings. This panel will discuss the substance and impact of these changes, as well as the Federal Court’s Revised Notice to the Profession on PM(NOC) proceedings.

  1. Promise of the Patent and Eli Lilly: Looking Toward the Future.

The much-anticipated NAFTA Tribunal decision in the Eli Lilly dispute marked a favourable outcome for the Government of Canada. However, that tribunal decision was not the final word on either the ‘promise of the patent’ doctrine, or on Chapter 11 NAFTA arbitration. The Supreme Court of Canada, in AstraZeneca v. Apotex, will decide whether the ‘promise’ doctrine has any place in Canadian law; while the future of NAFTA arbitration remains in the hands of Chapter 11 tribunals. This panel will discuss the AstraZeneca and Eli Lilly v. Government of Canada decisions, and address the broader issue of the future of Chapter 11 disputes and their possible impact on domestic law.

  1. Patents and the Competition Bureau: The New IP Enforcement Guidelines.

In an effort to update and modernize its enforcement mandate, the Competition Bureau revised its Intellectual Property Enforcement Guidelines (IPEGs) in 2016. This panel will discuss the substance of the 2016 changes as they relate to the activities of patent holders. The emerging on-the-ground impact of the revisions, as well as the status of the Competition Bureau’s ongoing annual review process, will also be addressed. Topics covered will include patent settlement agreements, patent assertion entities, product switching and standard essential patents.

  1. Comity, Stare Decisis, and the Optimal Development of Patent Doctrine.

Patent law doctrine emerges from the ongoing dialogue between the Supreme Court, the Federal Court of Appeal and the Federal Court. But the conversation between these learned benches does not proceed on stare decisis and comity alone: it takes place within a large zone of judicial discretion and legal interpretation. Disagreements often arise, for example, about what is binding and what is merely persuasive in SCC precedent. Is it better to adopt a narrow view of SCC precedent, thereby allowing judges to build on the judicial experience of the FC and FCA? And how should the FCA resolve new issues - by interpreting ambiguous SCC dicta, or by using its considerable expertise to engage in independent analysis? The issues of comity and stare decisis also arise at the FC/FCA level. Should the FCA be more proactive in overruling its own decisions, or wait for the SCC to change the law? This panel will discuss all aspects of the debate, with an eye towards balancing the competing goals of legal certainty and growth in the common law.


Fifth Annual University of Toronto Patent Colloquium

Friday, November 4, 2016 - 08:30 to 17:00

Location: Moot Court Room, Jackman Law Building, 78 Queen's Park

Download the agenda: 2016PatentColloquiumAgenda

Our keynote speaker was Agnès Lajoie, Assistant Commissioner of Patents, Canadian Intellectual Property Office. This year’s panels discussed: ‘Early Stage Claim Construction: Should it be Implemented in Canada?’; ‘Independence of Experts/Dealing with Bias’; ‘Non-infringing Alternatives in Patent Remedies’; and ‘A Tribute to the Jurisprudence and Scholarship of Justice Roger T. Hughes’. Speakers will include Chief Judge Leonard P. Stark, D. Delaware; Professor Sivaramjani Thambisetty, Law Department, London School of Economics;and Junyi Chen, Deeth Williams Wall. Moderators included Chief Justice Paul Crampton and Justice Elizabeth Heneghan, of the Federal Court of Canada.

Some of our panelists have agreed to share their presentation materials:

Panel 1: Early Stage Claim Construction: Should it be Implemented in Canada?

Panel Slides

Steven C. Carlson, Kasowitz, Benson, Torres, & Friedman LLP; Chief Judge Leonard P. Stark, U. S. District Court, D. Delaware; Scott MacKendrick, Bereskin & Parr LLP

Panel 2: Independence of Experts/Dealing with Bias 

Slides Prof. Sivaramjani Thambisetty, London School of Economics (LSE Law)

Slides Prof. Christopher Robertson, U. of Arizona, James E. Rogers College of Law

Slides Andrew Bernstein, Torys LLP

Panel 4: Non-Infringing Alternatives in Patent Remedies

Slides Prof. Norman Siebrasse, Faculty of Law, University of New Brunswick



4th Annual Patent Colloquium

Date: Friday, November 20, 2015

Location: Hart House Great Hall, 7 Hart House Circle


9:00 - 9:15                    Opening Remarks

  • Dean Edward Iacobucci, University of Toronto Faculty of Law
  • Chief Justice Paul Crampton, Federal Court of Canada
  • Prof. Simon Stern, Co-Director, Centre for Innovation Law and Policy

9:15 – 10:30                  Panel 1: Sound Prediction and the Promise of a Patent

Moderator: Justice Roger Hughes, Federal Court of Canada

  • Scott MacKendrick, Bereskin & Parr LLP
  • Marguerite Ethier, Lenczner Slaght Royce Smith Griffin LLP
  • Donald Cameron, Bereskin & Parr

10:30 – 10:45                Morning Tea Break 

10:45 - 12:00 pm           Panel 2: Has the time come for a Patent Office Court to determine Patent Validity?

Moderator: Dominique Hussey, Bennett Jones LLP 

  • Andrew Bernstein, Torys LLP
  • Richard Naiberg, Goodmans LLP
  • Timothy Gilbert, Gilbert’s LLP 

12:00 – 1:30                  Lunch and Keynote Speech

Keynote Speaker: Prof. Rochelle Dreyfuss, Pauline Newman Professor of Law, Co-Director of the Engelberg Center on Innovation Law and Policy,

New York University School of Law 

1:30 – 2:45                   Panel 3: The Evolving Landscape of Patent Remedies

Moderator: Prof. Margaret Jane Radin, University of Toronto Faculty of Law 

  • Prof. Ruth Okediji, University of Minnesota Law School
  • Prof. Justus Baron, Searle Center, Northwestern University School of Law
  • Prof. Christopher Seaman, Washington and Lee University, School of Law 

2:45 – 3:00                   Afternoon Tea Break

3:00 – 4:15                   Panel 4: International Arbitration (Eli Lilly v. Governmentt of Canada)

Moderator: Justice Russel Zinn, Federal Court of Canada

  • Alexander Stack, Cognition LLP
  • Prof. Talha Syed, University of California, Berkeley Law School
  • Prof. Andrew Torrance, University of Kansas School of Law

4:15 - 4:30                    Closing Remarks/Adjournment


Third Annual Patent Colloquium

Friday, November 21, 2014 - 09:00 to 16:30

Location: Great Hall at 7 Hart House Circle, Toronto, Ontario


8:30 a.m. – 9:00 a.m. Registration

9:00 a.m. – 9:15 a.m. Opening Remarks and Welcome

Panel #1 Sequential Innovation and Patent Pooling: Contemporary Perspectives
9:15 a.m. – 10:30 a.m.

Morning Break 10:30 a.m. – 10:45 a.m.

Panel #2 Patent Assertion Entities (PAE’s) as Market Makers or “Trolls”: A Moving Target
10:45 a.m. – 12:00 p.m.

Lunch and Keynote speech by Kathleen M. Sullivan, Quinn Emanuel Urquhart & Sullivan LLP.
12:00 p.m. – 1:30 p.m.

“Patent Law Goes to Washington: Balancing Protection and Innovation (Canadian-style) at the US Supreme Court”

Panel #3 User Innovation in Theory and Practice: Consequences for Patent Law
1:30 p.m. – 2:45 p.m.

Afternoon Break 2:45 p.m. – 3:00 p.m.

Panel #4 Standard-Essential Patents: Enforcement Options with FRAND Terms
3:00 p.m. – 4:15 p.m.

Made possible by a generous gift from Teva Canada


Second Annual Patent Colloquium

Friday, November 22, 2013 - 09:00 to 16:30

Location: Great Hall, 7 Hart House, Toronto, Ontario

Panel 1: Patent Advocacy

  • Chief Justice Paul Crampton, Federal Court of Canada
  • Judge Kathleen O’Malley, US Federal Circuit
  • Harry Marcus, LockeLord LLP (NY)
  • Andrew Bernstein, Torys
  • Mark Davis, Heenan Blaikie

Panel 2 — Is Canadian Patent Law Out of Step?

  • Justice Roger Hughes, Federal Court of Canada
  • Ildiko Mehes, Vice President & General Counsel, Teva North America, Generics
  • Prof. David Vaver, Osgoode Hall Law School
  • Prof. Richard Gold, McGill University Faculty of Law
  • Anthony Creber, Gowlings


Panel 3: Views from the Top

  • Prof. Ariel Katz, University of Toronto Faculty of Law
  • Justice Annabelle Bennett, Federal Court of Australia
  • Prof. Norman Siebrasse, University of New Brunswick
  • Prof. Andrew Torrance, University of Kansas
  • Prof. Toshiko Takenaka, University of Washington

Panel 4: Competition Law and IP

  • Prof. Ed Iacobucci, University of Toronto Faculty of Law
  • Prof. Ariel Katz, University of Toronto Faculty of Law
  • George Addy, Davies
  • Prof. Jay Thomas, Georgetown University Law Center
  • Catherine Lacavera, Director of Litigation, Google
  • Douglas Clark, Assistant Deputy Commissioner, Competition Bureau


2012 Patents Colloquium: From Bench to Bench: Pharmaceutical patents from Lab Bench to the Courtroom

Saturday, November 30, 2012 - 09:00 to 15:15

Location: Bennett Lecture Hall, Flavelle House 78 Queen's Park, Toronto, Ontario Canada


9:30                              Welcome from Dean Mayo Moran

9:30 - 9:35                    Opening Remarks 

The Honourable Justice Roger Hughes, Federal Court of Canada 

9:35 - 10:30                  Panel 1: The Science of Drug Development

Panel Lead: Dr. Jayson Parker, Medical Biotechnology Analyst

        UofT Master of Biotechnology Program


  • Dr. Bernard Chiasson; President, BJC Integrated Scientific Management Inc.
  • Dr. Aled Edwards; UofT Department of Medical Research and CEO, Structural
  • Genomics Consortium
  • Dr. Patricia Folkins; Bereskin & Parr
  • Professor Paul Grootendorst, UofT Leslie Dan Faculty of Pharmacy
  • Dr. Theodore Witek, President and CEO, Boehringer Ingelheim (Canada) Ltd.

10:30 - 10:45                Break

10:45 - 11:45                Panel 2: The Regulatory and Business Context in the Pharmaceutical


Panel Lead: Dr. Karen Burke; Director, Regulatory Affairs, Drug Safety and

Quality Assurance, Amgen Canada Inc.


  • William Charnetski, VP, Global Government Affairs, Public Policy and Corporate Responsibility, AstraZeneca plc
  • Benjamin Gray, VP, Legal and General Counsel, Mylan Pharmaceuticals ULC
  • David Lee; Director, Health Canada Office of Legislative and Regulatory Modernization
  • Professor Donald Light, Resident Fellow, Edmond J. Safra Center for Ethics, Harvard University
  • Darren Noseworthy, Vice-President and General Counsel, Pfizer Canada Inc.
  • Dr. Jayson Parker, Medical Biotechnology Analyst, UofT Master of Biotechnology Program 

11:45 - 12:45 p.m.         Lunch and Keynote Speech by The Honourable Justice Ian Binnie

12:45 - 1:45                  Panel 3: Does patent law help or hinder the business and science of drug development?

Panel Lead: Tim Gilbert, Gilberts LLP 


  • Marta Gross; Goodwin Procter (New York)
  • Patrick McGrade, Vice-President, Corporate & Legal Affairs, GlaxoSmithKline Inc.
  • ldiko Mehes, Vice-President and General Counsel, Teva Canada
  • Robert Shapiro; Global Lead Patent Attorney, Apotex Inc.
  • Alex Stack; Patent Counsel, Mylan Inc.
  • Roger Tam; Vice-President, Legal, Roche Canada
  • Alonzo Weems; General Counsel and Corporate Secretary, Eli Lilly Canada

1:45 - 2:00                    Break

2:00 - 3:00                    Panel 4: Advising the Court: The role of experts

Panel Lead: Donald Cameron; Bereskin & Parr


  • Dominique Hussey; Bennett Jones
  • Omar Jabri; Patent Counsel, Apotex Inc., former New York Patent Counsel
  • Robert MacFarlane, Bereskin & Parr
  • Andrew Reddon, McCarthy Tetrault
  • Andrew Shaughnessy, Torys
  • Jonathan Stainsby, Heenan Blaikie
  • Professor Janet Walker, Osgoode Hall Law School, Advisor to Federal Court Rules committee 

3:00 - 3:15                    Concluding Remarks